부산대학교 도서관

This study was undertaken to define the risk of AIDS in a cohort of 250 HIV-seropositive patients identified by their clinical and biological status. All patients were enrolled between October 1985 and March 1988. They were classified according lo clinical classes A, asymptomatic (n = 97); B. lymphadenopathic (n= 123); and C, AIDS-related complex. (n = 30). Also as CD4 cell stages 1 (CD4 ≥ 600/μl; n = 126); 2 (CD4 < 600 and ≥ 300/μl; n = 83); and 3 (CD4 < 300/μl; n = 41); and serum p24 antigen positive (n = 48) or negative (n = 202). All patients were evaluated every 3-6 months, until AIDS development or April 1989:29 cases of AIDS occurred during the follow-up period. The risk of AIDS in class C is very high (64% at 2 years) compared with the 3-year risk of classes A (13%) and B (25%). On the other hand the three CD4 stages have significantly different prognosis (stage 1 6%; stage 2 22%; and stage 3 89%; P<10-2). Antigen p24 negative and positive patients have also different prognosis (18% and 53%; P<10-4). Interestingly, p24 antigen conserved its prognostic value in stage 2 (positive 37%. negative 16%) while stages 1 are at low risk of AIDS and stages 3 at high risk whatever their p24 antigen status. We have also identified the risk of becoming stage 3 and/ or p24 antigen positive in p24 antigen negative patients at stages 1 and 2 (respectively, 18% and 47%). This classification should serve lo design randomized trials better with experimental drugs with earlier end-points than AIDS onset. [ABSTRACT FROM AUTHOR]